Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients
Previous immunohistochemical (IHC) studies showed controversial data about the prognostic value of tumor-infiltrating lymphocytes (TILs) in follicular lymphoma (FL). To clarify this issue, a large series of FL samples from rituximab-treated patients enrolled in the randomized PRIMA trial was examine...
Saved in:
| Published in | Human pathology Vol. 64; pp. 128 - 136 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.06.2017
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0046-8177 1532-8392 1532-8392 |
| DOI | 10.1016/j.humpath.2017.03.023 |
Cover
| Abstract | Previous immunohistochemical (IHC) studies showed controversial data about the prognostic value of tumor-infiltrating lymphocytes (TILs) in follicular lymphoma (FL). To clarify this issue, a large series of FL samples from rituximab-treated patients enrolled in the randomized PRIMA trial was examined. IHC was quantified using automated image analysis in 417, 287, 418, 406, 379, and 369 patients for CD3, CD4, CD8, PD1, ICOS, and FOXP3, respectively. RNAseq analysis was used to quantify TIL-related mRNA transcripts from 148 patients. When each IHC marker was used as a continuous variable in the whole cohort, high CD3 counts were associated with better progression-free survival (PFS) (P = .025). When an optimal IHC cut point was applied to the whole patient population, high CD3 counts and high PD1 counts were associated with better PFS (P = .011 and P = .044, respectively), whereas none of the other TIL markers had any significant correlation with outcome. When a stringent analysis was performed by dividing the whole cohort into a training set and a validation set, none of the TIL markers showed a prognostic significance in both groups. RNAseq analysis showed a significant correlation between high levels of CD3 and CD8 transcripts and better PFS (P = .001 and P = .037, respectively). No prognostic correlation was found as to the level of other immune gene transcripts. These results suggest that the IHC prognostic value of TILs is circumvented by rituximab treatment, although there is a trend for high numbers of CD3+ TILs to correlate with better PFS.
•In rituximab-treated FL patients, CD3+ cells are a prognostic indicator of better survival.•CD3+ cells are the strongest prognostic indicator compared to other classical TIL subsets.•The lack of robustness of the CD3 predictive value argues against its usefulness in routine practice. |
|---|---|
| AbstractList | Previous immunohistochemical (IHC) studies showed controversial data about the prognostic value of tumor-infiltrating lymphocytes (TILs) in follicular lymphoma (FL). To clarify this issue, a large series of FL samples from rituximab-treated patients enrolled in the randomized PRIMA trial was examined. IHC was quantified using automated image analysis in 417, 287, 418, 406, 379, and 369 patients for CD3, CD4, CD8, PD1, ICOS, and FOXP3, respectively. RNAseq analysis was used to quantify TIL-related mRNA transcripts from 148 patients. When each IHC marker was used as a continuous variable in the whole cohort, high CD3 counts were associated with better progression-free survival (PFS) (P= .025). When an optimal IHC cut point was applied to the whole patient population, high CD3 counts and high PD1 counts were associated with better PFS (P= .011 andP= .044, respectively), whereas none of the other TIL markers had any significant correlation with outcome. When a stringent analysis was performed by dividing the whole cohort into a training set and a validation set, none of the TIL markers showed a prognostic significance in both groups. RNAseq analysis showed a significant correlation between high levels ofCD3andCD8transcripts and better PFS (P= .001 andP= .037, respectively). No prognostic correlation was found as to the level of other immune gene transcripts. These results suggest that the IHC prognostic value of TILs is circumvented by rituximab treatment, although there is a trend for high numbers of CD3+ TILs to correlate with better PFS. Summary Previous immunohistochemical (IHC) studies showed controversial data about the prognostic value of tumor-infiltrating lymphocytes (TILs) in follicular lymphoma (FL). To clarify this issue, a large series of FL samples from rituximab-treated patients enrolled in the randomized PRIMA trial was examined. IHC was quantified using automated image analysis in 417, 287, 418, 406, 379, and 369 patients for CD3, CD4, CD8, PD1, ICOS, and FOXP3, respectively. RNAseq analysis was used to quantify TIL-related mRNA transcripts from 148 patients. When each IHC marker was used as a continuous variable in the whole cohort, high CD3 counts were associated with better progression-free survival (PFS) ( P = .025). When an optimal IHC cut point was applied to the whole patient population, high CD3 counts and high PD1 counts were associated with better PFS ( P = .011 and P = .044, respectively), whereas none of the other TIL markers had any significant correlation with outcome. When a stringent analysis was performed by dividing the whole cohort into a training set and a validation set, none of the TIL markers showed a prognostic significance in both groups. RNAseq analysis showed a significant correlation between high levels of CD3 and CD8 transcripts and better PFS ( P = .001 and P = .037, respectively). No prognostic correlation was found as to the level of other immune gene transcripts. These results suggest that the IHC prognostic value of TILs is circumvented by rituximab treatment, although there is a trend for high numbers of CD3+ TILs to correlate with better PFS. Previous immunohistochemical (IHC) studies showed controversial data about the prognostic value of tumor-infiltrating lymphocytes (TILs) in follicular lymphoma (FL). To clarify this issue, a large series of FL samples from rituximab-treated patients enrolled in the randomized PRIMA trial was examined. IHC was quantified using automated image analysis in 417, 287, 418, 406, 379, and 369 patients for CD3, CD4, CD8, PD1, ICOS, and FOXP3, respectively. RNAseq analysis was used to quantify TIL-related mRNA transcripts from 148 patients. When each IHC marker was used as a continuous variable in the whole cohort, high CD3 counts were associated with better progression-free survival (PFS) (P = .025). When an optimal IHC cut point was applied to the whole patient population, high CD3 counts and high PD1 counts were associated with better PFS (P = .011 and P = .044, respectively), whereas none of the other TIL markers had any significant correlation with outcome. When a stringent analysis was performed by dividing the whole cohort into a training set and a validation set, none of the TIL markers showed a prognostic significance in both groups. RNAseq analysis showed a significant correlation between high levels of CD3 and CD8 transcripts and better PFS (P = .001 and P = .037, respectively). No prognostic correlation was found as to the level of other immune gene transcripts. These results suggest that the IHC prognostic value of TILs is circumvented by rituximab treatment, although there is a trend for high numbers of CD3+ TILs to correlate with better PFS. Previous immunohistochemical (IHC) studies showed controversial data about the prognostic value of tumor-infiltrating lymphocytes (TILs) in follicular lymphoma (FL). To clarify this issue, a large series of FL samples from rituximab-treated patients enrolled in the randomized PRIMA trial was examined. IHC was quantified using automated image analysis in 417, 287, 418, 406, 379, and 369 patients for CD3, CD4, CD8, PD1, ICOS, and FOXP3, respectively. RNAseq analysis was used to quantify TIL-related mRNA transcripts from 148 patients. When each IHC marker was used as a continuous variable in the whole cohort, high CD3 counts were associated with better progression-free survival (PFS) (P = .025). When an optimal IHC cut point was applied to the whole patient population, high CD3 counts and high PD1 counts were associated with better PFS (P = .011 and P = .044, respectively), whereas none of the other TIL markers had any significant correlation with outcome. When a stringent analysis was performed by dividing the whole cohort into a training set and a validation set, none of the TIL markers showed a prognostic significance in both groups. RNAseq analysis showed a significant correlation between high levels of CD3 and CD8 transcripts and better PFS (P = .001 and P = .037, respectively). No prognostic correlation was found as to the level of other immune gene transcripts. These results suggest that the IHC prognostic value of TILs is circumvented by rituximab treatment, although there is a trend for high numbers of CD3+ TILs to correlate with better PFS.Previous immunohistochemical (IHC) studies showed controversial data about the prognostic value of tumor-infiltrating lymphocytes (TILs) in follicular lymphoma (FL). To clarify this issue, a large series of FL samples from rituximab-treated patients enrolled in the randomized PRIMA trial was examined. IHC was quantified using automated image analysis in 417, 287, 418, 406, 379, and 369 patients for CD3, CD4, CD8, PD1, ICOS, and FOXP3, respectively. RNAseq analysis was used to quantify TIL-related mRNA transcripts from 148 patients. When each IHC marker was used as a continuous variable in the whole cohort, high CD3 counts were associated with better progression-free survival (PFS) (P = .025). When an optimal IHC cut point was applied to the whole patient population, high CD3 counts and high PD1 counts were associated with better PFS (P = .011 and P = .044, respectively), whereas none of the other TIL markers had any significant correlation with outcome. When a stringent analysis was performed by dividing the whole cohort into a training set and a validation set, none of the TIL markers showed a prognostic significance in both groups. RNAseq analysis showed a significant correlation between high levels of CD3 and CD8 transcripts and better PFS (P = .001 and P = .037, respectively). No prognostic correlation was found as to the level of other immune gene transcripts. These results suggest that the IHC prognostic value of TILs is circumvented by rituximab treatment, although there is a trend for high numbers of CD3+ TILs to correlate with better PFS. Previous immunohistochemical (IHC) studies showed controversial data about the prognostic value of tumor-infiltrating lymphocytes (TILs) in follicular lymphoma (FL). To clarify this issue, a large series of FL samples from rituximab-treated patients enrolled in the randomized PRIMA trial was examined. IHC was quantified using automated image analysis in 417, 287, 418, 406, 379, and 369 patients for CD3, CD4, CD8, PD1, ICOS, and FOXP3, respectively. RNAseq analysis was used to quantify TIL-related mRNA transcripts from 148 patients. When each IHC marker was used as a continuous variable in the whole cohort, high CD3 counts were associated with better progression-free survival (PFS) (P = .025). When an optimal IHC cut point was applied to the whole patient population, high CD3 counts and high PD1 counts were associated with better PFS (P = .011 and P = .044, respectively), whereas none of the other TIL markers had any significant correlation with outcome. When a stringent analysis was performed by dividing the whole cohort into a training set and a validation set, none of the TIL markers showed a prognostic significance in both groups. RNAseq analysis showed a significant correlation between high levels of CD3 and CD8 transcripts and better PFS (P = .001 and P = .037, respectively). No prognostic correlation was found as to the level of other immune gene transcripts. These results suggest that the IHC prognostic value of TILs is circumvented by rituximab treatment, although there is a trend for high numbers of CD3+ TILs to correlate with better PFS. •In rituximab-treated FL patients, CD3+ cells are a prognostic indicator of better survival.•CD3+ cells are the strongest prognostic indicator compared to other classical TIL subsets.•The lack of robustness of the CD3 predictive value argues against its usefulness in routine practice. |
| Author | Morschhauser, Franck Szafer-Glusman, Edith Gelas-Dore, Benedicte Venstrom, Jeffrey M. Huet, Sarah Canioni, Danielle Cartron, Guillaume Bolen, Christopher R. Punnoose, Elizabeth Salles, Gilles Bouabdallah, Reda Laurent, Camille Xerri, Luc Olive, Daniel Brice, Pauline Dartigues-Cuilléres, Peggy Fabiani, Bettina Charlotte, Fréderic Chassagne-Clément, Catherine |
| Author_xml | – sequence: 1 givenname: Luc surname: Xerri fullname: Xerri, Luc email: xerril@ipc.unicancer.fr organization: Department of Bio-Pathology, Hematology, and Tumor Immunology, Institut Paoli-Calmettes and Aix-Marseille Univ, Marseille, France – sequence: 2 givenname: Sarah surname: Huet fullname: Huet, Sarah organization: INSERM1052, CNRS 5286, Centre de Recherche en Cancerologie de Lyon, Faculté de Médecine Lyon-Sud Charles Mérieux, Hospices Civils De Lyon, Laboratoire d'hématologie, F-69495 Pierre Bénite cedex – sequence: 3 givenname: Jeffrey M. surname: Venstrom fullname: Venstrom, Jeffrey M. organization: Genentech Inc., South San Francisco, CA 94080, USA – sequence: 4 givenname: Edith surname: Szafer-Glusman fullname: Szafer-Glusman, Edith organization: Genentech Inc., South San Francisco, CA 94080, USA – sequence: 5 givenname: Bettina surname: Fabiani fullname: Fabiani, Bettina organization: Department of Pathology, Centre Hospitalier Saint Antoine, F-75571 Paris, France – sequence: 6 givenname: Danielle surname: Canioni fullname: Canioni, Danielle organization: Department of Pathology, Centre Hospitalier Necker, F-75743 Paris, France – sequence: 7 givenname: Catherine surname: Chassagne-Clément fullname: Chassagne-Clément, Catherine organization: Department of Pathology, Centre, Léon Bérard, F-69373 Lyon, France – sequence: 8 givenname: Peggy surname: Dartigues-Cuilléres fullname: Dartigues-Cuilléres, Peggy organization: Department of Pathology, Institut Gustave Roussy, F-94805 Villejuif, France – sequence: 9 givenname: Fréderic surname: Charlotte fullname: Charlotte, Fréderic organization: Department of Pathology, Centre Hospitalier Pitié-Salpêtriére, F-75651 France – sequence: 10 givenname: Camille surname: Laurent fullname: Laurent, Camille organization: Department of Pathology, INSERM U.1037, Institut Universitaire du Cancer-Oncopole, F-31059 Toulouse – sequence: 11 givenname: Benedicte surname: Gelas-Dore fullname: Gelas-Dore, Benedicte organization: INSERM1052, CNRS 5286, Centre de Recherche en Cancerologie de Lyon, Faculté de Médecine Lyon-Sud Charles Mérieux, Hospices Civils De Lyon, Laboratoire d'hématologie, F-69495 Pierre Bénite cedex – sequence: 12 givenname: Christopher R. surname: Bolen fullname: Bolen, Christopher R. organization: Genentech Inc., South San Francisco, CA 94080, USA – sequence: 13 givenname: Elizabeth surname: Punnoose fullname: Punnoose, Elizabeth organization: Genentech Inc., South San Francisco, CA 94080, USA – sequence: 14 givenname: Reda surname: Bouabdallah fullname: Bouabdallah, Reda organization: Department of Bio-Pathology, Hematology, and Tumor Immunology, Institut Paoli-Calmettes and Aix-Marseille Univ, Marseille, France – sequence: 15 givenname: Pauline surname: Brice fullname: Brice, Pauline organization: Department of Hematology, Centre Hospitalier Saint Louis, F-75475 Paris, France – sequence: 16 givenname: Franck surname: Morschhauser fullname: Morschhauser, Franck organization: Department of Hematology, Hopital Claude Huriez, Unité GRITA, Université de Lille 2, F-59000 Lille, France – sequence: 17 givenname: Guillaume surname: Cartron fullname: Cartron, Guillaume organization: Departement of Hematology, CHU Montpellier, UMR CNRS-5235, F-34295 Montpellier, France – sequence: 18 givenname: Daniel surname: Olive fullname: Olive, Daniel organization: Department of Bio-Pathology, Hematology, and Tumor Immunology, Institut Paoli-Calmettes and Aix-Marseille Univ, Marseille, France – sequence: 19 givenname: Gilles surname: Salles fullname: Salles, Gilles organization: INSERM1052, CNRS 5286, Centre de Recherche en Cancerologie de Lyon, Faculté de Médecine Lyon-Sud Charles Mérieux, Hospices Civils De Lyon, Laboratoire d'hématologie, F-69495 Pierre Bénite cedex |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28414090$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUk1r3DAUFCWl2aT9CS2CXnqxqw9btiltKaFfECi06VnI8nNWW1naSHLI_vvI7IbCQklP0mFm3sy8d4ZOnHeA0EtKSkqoeLsp1_O0VWldMkKbkvCSMP4ErWjNWdHyjp2gFSGVKFraNKfoLMYNIZTWVf0MnbK2ohXpyArFnybNd2ZSPU4BVJrAJaxN0PN0m78RpzXgbfDXzsdkNDZ5pk7YjzjNkw-FcaOxKahk3DW-KjRYG7FxePTWGj1bFbDdTdu1nxTObs2i-Rw9HZWN8OLwnqPfXz5fXXwrLn98_X7x6bLQNWGpoENFBi5a3Wids7VVD7wflaLjoDuooWk5h0oDV00t2KCgYUJ1negBtG57wc_Rm71u9n8zQ0xyMnFxqBz4OUratm0nWCMW6Osj6MbPwWV3knaUCVE1hGfUqwNq7icY5Dbk4sJOPtSZAe_2AB18jAFGqU3Kqb3LFRkrKZHL8uRGHpYnl-VJwmUOmNn1EfthwGO8j3se5DJvDQQZdS5aw2AC6CQHbx5V-HCkoK1xRiv7B3YQ_3YhI5NE_loOa7kr2vB8U7TLAu__LfAfBu4BEV3jeg |
| CitedBy_id | crossref_primary_10_1177_03008916231221636 crossref_primary_10_1158_1078_0432_CCR_19_2973 crossref_primary_10_1002_jha2_1103 crossref_primary_10_1016_j_prp_2020_153096 crossref_primary_10_1007_s00277_022_04914_8 crossref_primary_10_1111_bjh_16414 crossref_primary_10_1111_cyt_12693 crossref_primary_10_1111_bjh_18881 crossref_primary_10_1007_s00432_019_02961_9 crossref_primary_10_1016_j_hoc_2020_02_007 crossref_primary_10_3324_haematol_2020_263194 crossref_primary_10_3390_ijms252011057 crossref_primary_10_1002_cam4_70117 crossref_primary_10_1002_cam4_1918 crossref_primary_10_1002_hon_2781 crossref_primary_10_1007_s00262_021_02945_0 crossref_primary_10_1038_s41598_019_50029_y crossref_primary_10_1007_s12185_018_2466_7 crossref_primary_10_1182_bloodadvances_2017015164 crossref_primary_10_1016_j_humpath_2017_09_018 crossref_primary_10_1182_bloodadvances_2020003774 crossref_primary_10_1016_j_humpath_2017_09_017 |
| Cites_doi | 10.1158/1078-0432.CCR-15-2023 10.1186/1479-5876-10-205 10.1182/blood-2011-04-345777 10.1038/cmi.2012.34 10.3324/haematol.2013.095257 10.1002/ijc.28937 10.1182/blood-2003-12-4434 10.1158/1078-0432.CCR-11-0264 10.3109/10428194.2012.734616 10.1200/JCO.2007.12.8298 10.1158/1078-0432.CCR-09-2487 10.1016/j.beha.2011.02.007 10.1016/j.humpath.2014.06.019 10.1136/jcp.2008.057257 10.1158/1078-0432.CCR-04-0713 10.1016/j.humpath.2010.08.015 10.1016/j.semcancer.2012.03.004 10.1200/JCO.2006.06.4642 10.1111/j.1469-7580.2008.00910.x 10.1158/1078-0432.CCR-13-2367 10.1200/JCO.2012.44.2137 10.1016/j.humpath.2012.03.025 10.1182/blood-2006-04-018218 10.1200/JCO.2006.06.4766 10.1016/S0140-6736(10)62175-7 10.1016/S1470-2045(15)00169-2 10.1002/pmic.200800936 10.1186/gb-2014-15-2-r29 10.4049/jimmunol.178.7.4051 10.1182/blood-2009-07-235598 10.1038/nrg2484 10.1056/NEJMoa041869 10.1200/JCO.2008.18.0513 10.1038/bjc.2015.291 10.1158/1078-0432.CCR-14-3253 |
| ContentType | Journal Article |
| Copyright | 2017 Elsevier Inc. Elsevier Inc. Copyright © 2017 Elsevier Inc. All rights reserved. Copyright Elsevier Limited Jun 1, 2017 |
| Copyright_xml | – notice: 2017 Elsevier Inc. – notice: Elsevier Inc. – notice: Copyright © 2017 Elsevier Inc. All rights reserved. – notice: Copyright Elsevier Limited Jun 1, 2017 |
| CorporateAuthor | a LYSA study |
| CorporateAuthor_xml | – name: a LYSA study |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. 7X8 |
| DOI | 10.1016/j.humpath.2017.03.023 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1532-8392 |
| EndPage | 136 |
| ExternalDocumentID | 28414090 10_1016_j_humpath_2017_03_023 S0046817717301119 1_s2_0_S0046817717301119 |
| Genre | Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Institut Paoli-Calmettes – fundername: Roche funderid: http://dx.doi.org/10.13039/100004337 |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1CY 1P~ 1RT 1~. 1~5 3O- 4.4 457 4CK 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQOH AAQQT AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABLJU ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHHHB AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV BPHCQ BVXVI CAG COF DU5 EBS EFJIC EFKBS EJD EMOBN EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HDY HMK HMO HVGLF HZ~ IH2 IHE J1W J5H K-O KOM L7B M29 M41 MO0 N9A O-L O9- OAUVE OG0 OS0 OZT P-8 P-9 P2P PC. PQQKQ PROAC Q38 R2- ROL RPZ SAE SDF SDG SDP SEL SES SEW SJN SPCBC SSH SSZ SV3 T5K UGJ UHS UNMZH UV1 WUQ X7M Z5R ZGI ~G- 3V. 7X7 8FI AACTN AFCTW AFKRA AFKWA AJOXV AMFUW AZQEC BENPR FYUFA GUQSH M1P M2O RIG AAIAV ABLVK ABYKQ AHPSJ AJBFU EFLBG LCYCR ZA5 AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM K9. 7X8 ACLOT ~HD |
| ID | FETCH-LOGICAL-c502t-1d40d368c7cc02384be3bfaa1fdc9e5e7833e4ce3a7562dae726a996beecc8b63 |
| IEDL.DBID | AIKHN |
| ISSN | 0046-8177 1532-8392 |
| IngestDate | Sat Sep 27 20:30:41 EDT 2025 Fri Jul 25 06:17:00 EDT 2025 Wed Feb 19 02:36:29 EST 2025 Thu Apr 24 23:02:21 EDT 2025 Tue Jul 01 02:24:23 EDT 2025 Fri Feb 23 02:24:39 EST 2024 Tue Feb 25 19:55:52 EST 2025 Tue Aug 26 16:56:46 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Immunohistochemistry Follicular lymphoma Prognosis Microenvironment RNAseq |
| Language | English |
| License | Copyright © 2017 Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c502t-1d40d368c7cc02384be3bfaa1fdc9e5e7833e4ce3a7562dae726a996beecc8b63 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| PMID | 28414090 |
| PQID | 1912664703 |
| PQPubID | 105547 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_1888962766 proquest_journals_1912664703 pubmed_primary_28414090 crossref_citationtrail_10_1016_j_humpath_2017_03_023 crossref_primary_10_1016_j_humpath_2017_03_023 elsevier_sciencedirect_doi_10_1016_j_humpath_2017_03_023 elsevier_clinicalkeyesjournals_1_s2_0_S0046817717301119 elsevier_clinicalkey_doi_10_1016_j_humpath_2017_03_023 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2017-06-01 |
| PublicationDateYYYYMMDD | 2017-06-01 |
| PublicationDate_xml | – month: 06 year: 2017 text: 2017-06-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Philadelphia |
| PublicationTitle | Human pathology |
| PublicationTitleAlternate | Hum Pathol |
| PublicationYear | 2017 |
| Publisher | Elsevier Inc Elsevier Limited |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier Limited |
| References | Kiaii, Clear, Ramsay (bb0025) 2013; 31 Camp, Dolled-Filhart, Rimm (bb0135) 2004; 10 Canioni, Salles, Mounier (bb0160) 2008; 26 Dave, Wright, Tan (bb0020) 2004; 351 Voo, Foglietta, Percivalle (bb0085) 2014; 135 Kridel, Xerri, Gelas-Dore (bb0120) 2015; 21 Solal-Celigny, Roy, Colombat (bb0010) 2004; 104 Carreras, Lopez-Guillermo, Fox (bb0030) 2006; 108 Koch, Hoster, Unterhalt (bb0055) 2012; 43 Sander, de Jong, Rosenwald (bb0095) 2014; 99 Decaestecker, Lopez, D'Haene (bb0105) 2009; 9 Wahlin, Sundström, Holte (bb0070) 2011; 17 Law, Chen, Shi, Smyth (bb0140) 2014; 15 Lejeune, Jaen, Pons (bb0100) 2008; 212 de Jong, Fest (bb0080) 2011; 24 Alvaro, Lejeune, Salvado (bb0040) 2006; 24 Wang, Gerstein, Snyder (bb0130) 2009; 10 Carreras, Lopez-Guillermo, Roncador (bb0035) 2009; 27 Farinha, Al-Tourah, Gill, Klasa, Connors, Gascoyne (bb0065) 2010; 115 de Jong, Xie, Rosenwald (bb0090) 2009; 62 Whiteside (bb0175) 2012; 22 Xerri, Bachy, Fabiani (bb0110) 2014; 45 Galon, Pagès, Marincola (bb0145) 2012; 10 Dou, Feng, Liu, Wang (bb0170) 2012; 9 Nelson, Mansfield, Lloyd (bb0075) 2015; 113 Pulte, Jansen, Gondos (bb0005) 2013; 54 Hilchey, De, Rimsza, Bankert, Bernstein (bb0165) 2007; 178 Lee, Clear, Calaminici (bb0045) 2006; 24 Salles, Seymour, Offner (bb0125) 2011; 377 Smeltzer, Jones, Ziesmer (bb0060) 2014; 20 Nielsen, Sedgwick, Shahid (bb0155) 2016; 22 Wahlin, Aggarwal, Montes-Moreno (bb0115) 2010; 16 Pastore, Jurinovic, Kridel, Hoster, Staiger, Szczepanowski (bb0015) 2015; 16 Richendollar, Pohlman, Elson, Hsi (bb0050) 2011; 42 Laurent, Müller, Do (bb0150) 2011; 118 Wahlin (10.1016/j.humpath.2017.03.023_bb0070) 2011; 17 Nelson (10.1016/j.humpath.2017.03.023_bb0075) 2015; 113 Alvaro (10.1016/j.humpath.2017.03.023_bb0040) 2006; 24 Pulte (10.1016/j.humpath.2017.03.023_bb0005) 2013; 54 Lee (10.1016/j.humpath.2017.03.023_bb0045) 2006; 24 de Jong (10.1016/j.humpath.2017.03.023_bb0080) 2011; 24 Nielsen (10.1016/j.humpath.2017.03.023_bb0155) 2016; 22 Dou (10.1016/j.humpath.2017.03.023_bb0170) 2012; 9 Lejeune (10.1016/j.humpath.2017.03.023_bb0100) 2008; 212 Camp (10.1016/j.humpath.2017.03.023_bb0135) 2004; 10 de Jong (10.1016/j.humpath.2017.03.023_bb0090) 2009; 62 Kiaii (10.1016/j.humpath.2017.03.023_bb0025) 2013; 31 Galon (10.1016/j.humpath.2017.03.023_bb0145) 2012; 10 Farinha (10.1016/j.humpath.2017.03.023_bb0065) 2010; 115 Law (10.1016/j.humpath.2017.03.023_bb0140) 2014; 15 Sander (10.1016/j.humpath.2017.03.023_bb0095) 2014; 99 Wahlin (10.1016/j.humpath.2017.03.023_bb0115) 2010; 16 Voo (10.1016/j.humpath.2017.03.023_bb0085) 2014; 135 Smeltzer (10.1016/j.humpath.2017.03.023_bb0060) 2014; 20 Wang (10.1016/j.humpath.2017.03.023_bb0130) 2009; 10 Laurent (10.1016/j.humpath.2017.03.023_bb0150) 2011; 118 Decaestecker (10.1016/j.humpath.2017.03.023_bb0105) 2009; 9 Whiteside (10.1016/j.humpath.2017.03.023_bb0175) 2012; 22 Carreras (10.1016/j.humpath.2017.03.023_bb0030) 2006; 108 Carreras (10.1016/j.humpath.2017.03.023_bb0035) 2009; 27 Hilchey (10.1016/j.humpath.2017.03.023_bb0165) 2007; 178 Richendollar (10.1016/j.humpath.2017.03.023_bb0050) 2011; 42 Kridel (10.1016/j.humpath.2017.03.023_bb0120) 2015; 21 Canioni (10.1016/j.humpath.2017.03.023_bb0160) 2008; 26 Solal-Celigny (10.1016/j.humpath.2017.03.023_bb0010) 2004; 104 Dave (10.1016/j.humpath.2017.03.023_bb0020) 2004; 351 Salles (10.1016/j.humpath.2017.03.023_bb0125) 2011; 377 Xerri (10.1016/j.humpath.2017.03.023_bb0110) 2014; 45 Pastore (10.1016/j.humpath.2017.03.023_bb0015) 2015; 16 Koch (10.1016/j.humpath.2017.03.023_bb0055) 2012; 43 29126835 - Hum Pathol. 2018 Feb;72:198-199 29129542 - Hum Pathol. 2018 Feb;72:197-198 |
| References_xml | – volume: 42 start-page: 552 year: 2011 end-page: 557 ident: bb0050 article-title: Follicular programmed death 1–positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma publication-title: Hum Pathol – volume: 24 start-page: 5350 year: 2006 end-page: 5357 ident: bb0040 article-title: Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients publication-title: J Clin Oncol – volume: 104 start-page: 1258 year: 2004 end-page: 1265 ident: bb0010 article-title: Follicular lymphoma international prognostic index publication-title: Blood – volume: 113 start-page: 1197 year: 2015 end-page: 1205 ident: bb0075 article-title: Automated prognostic pattern detection shows favourable diffuse pattern of FOXP3(+) Tregs in follicular lymphoma publication-title: Br J Cancer – volume: 24 start-page: 135 year: 2011 end-page: 146 ident: bb0080 article-title: The microenvironment in follicular lymphoma publication-title: Best Pract Res Clin Haematol – volume: 45 start-page: 2085 year: 2014 end-page: 2093 ident: bb0110 article-title: Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis publication-title: Hum Pathol – volume: 9 start-page: 482 year: 2012 end-page: 488 ident: bb0170 article-title: Cyclic adenosine monophosphate involvement in low-dose cyclophosphamide-reversed immune evasion in a mouse lymphoma model publication-title: Cell Mol Immunol – volume: 43 start-page: 2274 year: 2012 end-page: 2281 ident: bb0055 article-title: The composition of the microenvironment in follicular lymphoma is associated with the stage of the disease publication-title: Hum Pathol – volume: 9 start-page: 4478 year: 2009 end-page: 4494 ident: bb0105 article-title: Requirements for the valid quantification of immunostains on tissue microarray materials using image analysis publication-title: Proteomics – volume: 10 start-page: 7252 year: 2004 end-page: 7259 ident: bb0135 article-title: X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization publication-title: Clin Cancer Res – volume: 22 start-page: 327 year: 2012 end-page: 334 ident: bb0175 article-title: What are regulatory T cells (Treg) regulating in cancer and why? publication-title: Semin Cancer Biol – volume: 17 start-page: 4136 year: 2011 end-page: 4144 ident: bb0070 article-title: T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab publication-title: Clin Cancer Res – volume: 22 start-page: 2226 year: 2016 end-page: 2236 ident: bb0155 article-title: Toward personalized lymphoma immunotherapy: identification of common driver mutations recognized by patient CD8+ T cells publication-title: Clin Cancer Res – volume: 135 start-page: 2834 year: 2014 end-page: 2846 ident: bb0085 article-title: Selective targeting of toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma publication-title: Int J Cancer – volume: 108 start-page: 2957 year: 2006 end-page: 2964 ident: bb0030 article-title: High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma publication-title: Blood – volume: 54 start-page: 979 year: 2013 end-page: 985 ident: bb0005 article-title: Survival of patients with non-Hodgkin lymphoma in Germany in the early 21st century publication-title: Leuk Lymphoma – volume: 377 start-page: 42 year: 2011 end-page: 51 ident: bb0125 article-title: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial publication-title: Lancet – volume: 15 start-page: R29 year: 2014 ident: bb0140 article-title: Voom: precision weights unlock linear model analysis tools for RNA-seq read counts publication-title: Genome Biol – volume: 178 start-page: 4051 year: 2007 end-page: 4061 ident: bb0165 article-title: Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8+CD25− and CD4+CD25− T cells publication-title: J Immunol – volume: 118 start-page: 5371 year: 2011 end-page: 5379 ident: bb0150 article-title: Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study publication-title: Blood – volume: 10 start-page: 57 year: 2009 end-page: 63 ident: bb0130 article-title: RNA-Seq: a revolutionary tool for transcriptomics publication-title: Nat Rev Genet – volume: 16 start-page: 1111 year: 2015 end-page: 1122 ident: bb0015 article-title: Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry publication-title: Lancet Oncol – volume: 212 start-page: 868 year: 2008 end-page: 878 ident: bb0100 article-title: Quantification of diverse subcellular immunohistochemical markers with clinicobiological relevancies: validation of a new computer-assisted image analysis procedure publication-title: J Anat – volume: 16 start-page: 637 year: 2010 end-page: 650 ident: bb0115 article-title: A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1–positive, regulatory, cytotoxic, and helper T cells and macrophages publication-title: Clin Cancer Res – volume: 10 start-page: 205 year: 2012 ident: bb0145 article-title: Cancer classification using the Immunoscore: a worldwide task force publication-title: J Transl Med – volume: 62 start-page: 128 year: 2009 end-page: 138 ident: bb0090 article-title: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg lymphoma biomarker consortium) publication-title: J Clin Pathol – volume: 351 start-page: 2159 year: 2004 end-page: 2169 ident: bb0020 article-title: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells publication-title: N Engl J Med – volume: 21 start-page: 3428 year: 2015 end-page: 3435 ident: bb0120 article-title: The prognostic impact of CD163-positive macrophages in follicular lymphoma: a study from the BC Cancer Agency and the Lymphoma Study Association publication-title: Clin Cancer Res – volume: 99 start-page: 715 year: 2014 end-page: 725 ident: bb0095 article-title: The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg lymphoma biomarker consortium publication-title: Haematologica – volume: 20 start-page: 2862 year: 2014 end-page: 2872 ident: bb0060 article-title: Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma publication-title: Clin Cancer Res – volume: 31 start-page: 2654 year: 2013 end-page: 2661 ident: bb0025 article-title: Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation publication-title: J Clin Oncol – volume: 27 start-page: 1470 year: 2009 end-page: 1476 ident: bb0035 article-title: High numbers of tumor-infiltrating programmed cell death 1–positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma publication-title: J Clin Oncol – volume: 115 start-page: 289 year: 2010 end-page: 295 ident: bb0065 article-title: The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation publication-title: Blood – volume: 26 start-page: 440 year: 2008 end-page: 446 ident: bb0160 article-title: High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial publication-title: J Clin Oncol – volume: 24 start-page: 5052 year: 2006 end-page: 5059 ident: bb0045 article-title: Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome publication-title: J Clin Oncol – volume: 22 start-page: 2226 year: 2016 ident: 10.1016/j.humpath.2017.03.023_bb0155 article-title: Toward personalized lymphoma immunotherapy: identification of common driver mutations recognized by patient CD8+ T cells publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-15-2023 – volume: 10 start-page: 205 year: 2012 ident: 10.1016/j.humpath.2017.03.023_bb0145 article-title: Cancer classification using the Immunoscore: a worldwide task force publication-title: J Transl Med doi: 10.1186/1479-5876-10-205 – volume: 118 start-page: 5371 year: 2011 ident: 10.1016/j.humpath.2017.03.023_bb0150 article-title: Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study publication-title: Blood doi: 10.1182/blood-2011-04-345777 – volume: 9 start-page: 482 year: 2012 ident: 10.1016/j.humpath.2017.03.023_bb0170 article-title: Cyclic adenosine monophosphate involvement in low-dose cyclophosphamide-reversed immune evasion in a mouse lymphoma model publication-title: Cell Mol Immunol doi: 10.1038/cmi.2012.34 – volume: 99 start-page: 715 year: 2014 ident: 10.1016/j.humpath.2017.03.023_bb0095 article-title: The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg lymphoma biomarker consortium publication-title: Haematologica doi: 10.3324/haematol.2013.095257 – volume: 135 start-page: 2834 year: 2014 ident: 10.1016/j.humpath.2017.03.023_bb0085 article-title: Selective targeting of toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma publication-title: Int J Cancer doi: 10.1002/ijc.28937 – volume: 104 start-page: 1258 year: 2004 ident: 10.1016/j.humpath.2017.03.023_bb0010 article-title: Follicular lymphoma international prognostic index publication-title: Blood doi: 10.1182/blood-2003-12-4434 – volume: 17 start-page: 4136 year: 2011 ident: 10.1016/j.humpath.2017.03.023_bb0070 article-title: T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-0264 – volume: 54 start-page: 979 year: 2013 ident: 10.1016/j.humpath.2017.03.023_bb0005 article-title: Survival of patients with non-Hodgkin lymphoma in Germany in the early 21st century publication-title: Leuk Lymphoma doi: 10.3109/10428194.2012.734616 – volume: 26 start-page: 440 year: 2008 ident: 10.1016/j.humpath.2017.03.023_bb0160 article-title: High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial publication-title: J Clin Oncol doi: 10.1200/JCO.2007.12.8298 – volume: 16 start-page: 637 year: 2010 ident: 10.1016/j.humpath.2017.03.023_bb0115 article-title: A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1–positive, regulatory, cytotoxic, and helper T cells and macrophages publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-09-2487 – volume: 24 start-page: 135 year: 2011 ident: 10.1016/j.humpath.2017.03.023_bb0080 article-title: The microenvironment in follicular lymphoma publication-title: Best Pract Res Clin Haematol doi: 10.1016/j.beha.2011.02.007 – volume: 45 start-page: 2085 year: 2014 ident: 10.1016/j.humpath.2017.03.023_bb0110 article-title: Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis publication-title: Hum Pathol doi: 10.1016/j.humpath.2014.06.019 – volume: 62 start-page: 128 year: 2009 ident: 10.1016/j.humpath.2017.03.023_bb0090 article-title: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg lymphoma biomarker consortium) publication-title: J Clin Pathol doi: 10.1136/jcp.2008.057257 – volume: 10 start-page: 7252 year: 2004 ident: 10.1016/j.humpath.2017.03.023_bb0135 article-title: X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-04-0713 – volume: 42 start-page: 552 year: 2011 ident: 10.1016/j.humpath.2017.03.023_bb0050 article-title: Follicular programmed death 1–positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma publication-title: Hum Pathol doi: 10.1016/j.humpath.2010.08.015 – volume: 22 start-page: 327 year: 2012 ident: 10.1016/j.humpath.2017.03.023_bb0175 article-title: What are regulatory T cells (Treg) regulating in cancer and why? publication-title: Semin Cancer Biol doi: 10.1016/j.semcancer.2012.03.004 – volume: 24 start-page: 5052 year: 2006 ident: 10.1016/j.humpath.2017.03.023_bb0045 article-title: Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome publication-title: J Clin Oncol doi: 10.1200/JCO.2006.06.4642 – volume: 212 start-page: 868 year: 2008 ident: 10.1016/j.humpath.2017.03.023_bb0100 article-title: Quantification of diverse subcellular immunohistochemical markers with clinicobiological relevancies: validation of a new computer-assisted image analysis procedure publication-title: J Anat doi: 10.1111/j.1469-7580.2008.00910.x – volume: 20 start-page: 2862 year: 2014 ident: 10.1016/j.humpath.2017.03.023_bb0060 article-title: Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-13-2367 – volume: 31 start-page: 2654 year: 2013 ident: 10.1016/j.humpath.2017.03.023_bb0025 article-title: Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation publication-title: J Clin Oncol doi: 10.1200/JCO.2012.44.2137 – volume: 43 start-page: 2274 year: 2012 ident: 10.1016/j.humpath.2017.03.023_bb0055 article-title: The composition of the microenvironment in follicular lymphoma is associated with the stage of the disease publication-title: Hum Pathol doi: 10.1016/j.humpath.2012.03.025 – volume: 108 start-page: 2957 year: 2006 ident: 10.1016/j.humpath.2017.03.023_bb0030 article-title: High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma publication-title: Blood doi: 10.1182/blood-2006-04-018218 – volume: 24 start-page: 5350 year: 2006 ident: 10.1016/j.humpath.2017.03.023_bb0040 article-title: Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients publication-title: J Clin Oncol doi: 10.1200/JCO.2006.06.4766 – volume: 377 start-page: 42 year: 2011 ident: 10.1016/j.humpath.2017.03.023_bb0125 article-title: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(10)62175-7 – volume: 16 start-page: 1111 year: 2015 ident: 10.1016/j.humpath.2017.03.023_bb0015 article-title: Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)00169-2 – volume: 9 start-page: 4478 year: 2009 ident: 10.1016/j.humpath.2017.03.023_bb0105 article-title: Requirements for the valid quantification of immunostains on tissue microarray materials using image analysis publication-title: Proteomics doi: 10.1002/pmic.200800936 – volume: 15 start-page: R29 year: 2014 ident: 10.1016/j.humpath.2017.03.023_bb0140 article-title: Voom: precision weights unlock linear model analysis tools for RNA-seq read counts publication-title: Genome Biol doi: 10.1186/gb-2014-15-2-r29 – volume: 178 start-page: 4051 issue: 7 year: 2007 ident: 10.1016/j.humpath.2017.03.023_bb0165 article-title: Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8+CD25− and CD4+CD25− T cells publication-title: J Immunol doi: 10.4049/jimmunol.178.7.4051 – volume: 115 start-page: 289 year: 2010 ident: 10.1016/j.humpath.2017.03.023_bb0065 article-title: The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation publication-title: Blood doi: 10.1182/blood-2009-07-235598 – volume: 10 start-page: 57 year: 2009 ident: 10.1016/j.humpath.2017.03.023_bb0130 article-title: RNA-Seq: a revolutionary tool for transcriptomics publication-title: Nat Rev Genet doi: 10.1038/nrg2484 – volume: 351 start-page: 2159 year: 2004 ident: 10.1016/j.humpath.2017.03.023_bb0020 article-title: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells publication-title: N Engl J Med doi: 10.1056/NEJMoa041869 – volume: 27 start-page: 1470 year: 2009 ident: 10.1016/j.humpath.2017.03.023_bb0035 article-title: High numbers of tumor-infiltrating programmed cell death 1–positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma publication-title: J Clin Oncol doi: 10.1200/JCO.2008.18.0513 – volume: 113 start-page: 1197 year: 2015 ident: 10.1016/j.humpath.2017.03.023_bb0075 article-title: Automated prognostic pattern detection shows favourable diffuse pattern of FOXP3(+) Tregs in follicular lymphoma publication-title: Br J Cancer doi: 10.1038/bjc.2015.291 – volume: 21 start-page: 3428 year: 2015 ident: 10.1016/j.humpath.2017.03.023_bb0120 article-title: The prognostic impact of CD163-positive macrophages in follicular lymphoma: a study from the BC Cancer Agency and the Lymphoma Study Association publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-3253 – reference: 29129542 - Hum Pathol. 2018 Feb;72:197-198 – reference: 29126835 - Hum Pathol. 2018 Feb;72:198-199 |
| SSID | ssj0011545 |
| Score | 2.336331 |
| Snippet | Previous immunohistochemical (IHC) studies showed controversial data about the prognostic value of tumor-infiltrating lymphocytes (TILs) in follicular lymphoma... Summary Previous immunohistochemical (IHC) studies showed controversial data about the prognostic value of tumor-infiltrating lymphocytes (TILs) in follicular... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 128 |
| SubjectTerms | Antineoplastic Agents - therapeutic use Automation Biomarkers Biomarkers, Tumor - analysis Biomarkers, Tumor - genetics Biopsy Cancer therapies CD3 Complex - analysis CD3 Complex - genetics Cloning Cytotoxicity Disease-Free Survival Follicular lymphoma Gene expression Humans Image Interpretation, Computer-Assisted Immunohistochemistry Immunotherapy Lymphocytes, Tumor-Infiltrating - drug effects Lymphocytes, Tumor-Infiltrating - immunology Lymphoma Lymphoma, Follicular - drug therapy Lymphoma, Follicular - genetics Lymphoma, Follicular - immunology Lymphoma, Follicular - pathology Microenvironment Monoclonal antibodies Pathology Patients Predictive Value of Tests Prognosis Rituximab - therapeutic use RNA, Messenger - genetics RNAseq Sequence Analysis, RNA Studies T-Lymphocytes - drug effects T-Lymphocytes - immunology Targeted cancer therapy Time Factors Treatment Outcome Tumor Microenvironment |
| Title | Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0046817717301119 https://www.clinicalkey.es/playcontent/1-s2.0-S0046817717301119 https://dx.doi.org/10.1016/j.humpath.2017.03.023 https://www.ncbi.nlm.nih.gov/pubmed/28414090 https://www.proquest.com/docview/1912664703 https://www.proquest.com/docview/1888962766 |
| Volume | 64 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB6SDZReSt_ZNA0q9OpdP7SS9hhCw7ZLcggJzU3Istw67NphvYbm0t_eGVt2KG1I6cn4MUjM85M1MwL4yB0VfIYZGhKaG0edCEyqkoBnGfpJE4W2LRQ-OxeLK_7lena9Ayd9LQylVXrf3_n01lv7J1PPzeltUVCNLxcqkrSNTAemz3dhL8Zor0awd_x5uTgfNhMIJXQbzSIggvtCnunN5DtyDbEWJXnJtt1pnDwUoh6CoG0oOn0OzzyGZMfdNF_AjitfwpMzv0v-CuqLYtv8KNYmZUMeObPFxjZrym6sGYI-RolZZUVdmllXKcmqnG2bdbUJUOmKVdtOt_zGLgP6t1-zomQ5NfBu81bZ6g61oFob5vuy1q_h6vTT5cki8IcrBHYWxtsgyniYJUJZaS3FbZ66JM2NifLMzt3MSZUkjluXGIkQKTNOxsLg4ih1KHSViuQNjMqqdPvA0OxzFIA1uNzlNpZ4DZ0woculFOlcjIH3_NTWdx6nAzBWuk8xu9FeDJrEoMNE45TGMBnIbrvWG48RiF5Yuq8rRU-oMTg8Rij_Ruhqb8-1jnQd61D_oXNjUAPlb2r7L4Me9vqk78eZR4iYOLrhMXwYXqPFk6hN6aoGv1FK0ZFJAhn7ttPDgT8INqiDWXjw__N6B0_prkuHO4TRdtO49wi8tukR7E5-RkfevOi6vPi6_AVIMjC- |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB7SDbS9lL67bdKq0Kuzfmgl7zGEhk2T3UPZQG5CluXGYdcOaxvaf98ZW3YoTUjIyWB5kJiXPlnzAPjGLSV8-ikaEpobR53wdBJHHk9T9JM68E2bKLxYivk5_3ExvdiBoz4XhsIqne_vfHrrrd2biePm5DrPKceXiziQdI1MDdNnT2CXU1PrEewenpzOl8NlAqGE7qJZeERwk8gzuTq4RK4h1qIgL9mWOw2ju7aouyBouxUdv4QXDkOyw26Zr2DHFq_h6cLdkr-B6mdeN7_zjU7YEEfOTL41zYaiGyuGoI9RYFZRUpVm1mVKsjJjdbMptx4qXb5uy-kWv9jKo3_7FcsLllEB7zZula3_oBaUG81cXdbqLZwff18dzT3XXMEzUz-svSDlfhqJ2EhjaN_miY2STOsgS83MTq2Mo8hyYyMtESKl2spQaDwcJRaFHiciegejoizsB2Bo9hkKwGg87nITSnz6VmjfZlKKZCbGwHt-KuMqj1MDjLXqQ8yulBODIjEoP1K4pDEcDGTXXemN-whELyzV55WiJ1S4OdxHKG8jtJWz50oFqgqVr_7TuTHEA-U_avuQSfd6fVI388wCREwc3fAYvg7DaPEkal3YssFv4jimlkkCGfu-08OBPwg2qIKZ__Hx6_oCz-arxZk6O1mefoLnNNKFxu3BqN42dh9BWJ18dkb2F-i1MQE |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rituximab+treatment+circumvents+the+prognostic+impact+of+tumor-infiltrating+T-cells+in+follicular+lymphoma+patients&rft.jtitle=Human+pathology&rft.au=Xerri%2C+Luc&rft.au=Huet%2C+Sarah&rft.au=Venstrom%2C+Jeffrey+M&rft.au=Szafer-Glusman%2C+Edith&rft.date=2017-06-01&rft.eissn=1532-8392&rft.volume=64&rft.spage=128&rft_id=info:doi/10.1016%2Fj.humpath.2017.03.023&rft_id=info%3Apmid%2F28414090&rft.externalDocID=28414090 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00468177%2Fcov200h.gif |